Isoform-Selective Calcineurin Inhibition: Market Intelligence, Male Contraceptive Potential, Neuroprotection, and High-Purity Phosphatase Reagents.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PPP3CC (Calcineurin Catalytic Subunit Gamma) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PPP3CC Full-Length / Catalytic Domain Protein High purity (>95%), Sequence Verified, Endotoxin <1EU/µg. Active phosphatase available. |
View PPP3CC Products |
| Isoform Panel | PPP3CA + PPP3CB Catalytic Subunits For selectivity counter-screening against alpha/beta isoforms. |
View PPP3CA Products View PPP3CB Products |
| Regulatory Subunit | PPP3R2 (Calcineurin B2) Testis-specific regulatory subunit for heterodimer holoenzyme reconstitution. |
View PPP3R2 Products |
| Gene Delivery | PPP3CC Premade ORF / Lentivirus CMV promoter, Puromycin selection, for stable cell line generation. |
View PPP3CC Products |
| Validator | PPP3CC siRNA Set (3 unique sequences) For knockdown validation and specificity confirmation. |
View PPP3CC Products |
| Substrate Control | NFATC1 (Partial) Dephosphorylation substrate for functional calcineurin assays. |
View NFATC1 Products |
| Benchmark Ab | Anti-PPP3CC Recombinant positive control for Western/immunoassays. | View PPP3CC Products |
| Related Target A | PPP3CA (Calcineurin Alpha) Dominant immune cell isoform; critical for selectivity profiling. |
View PPP3CA Products |
| Related Target B | PPP3R1 (Calcineurin B1) Ubiquitous regulatory subunit; alternative holoenzyme partner. |
View PPP3R1 Products |
| Related Target C | PPIA (Cyclophilin A) Immunophilin complex partner for cyclosporine-mediated calcineurin inhibition. |
View PPIA Products |
| Related Target D | FKBP1A (FKBP12) Key co-receptor for FK506-mediated calcineurin targeting; useful for ternary complex studies. |
View FKBP1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (vs PPP3CA/B) | Human PPP3CC, PPP3CA, and PPP3CB proteins available as matched set; >95% purity; sequence-verified for off-target liability assessment. |
| Holoenzyme Reconstitution | PPP3R2 (testis-specific) and PPP3R1 proteins provided for heterodimer formation assays; Ca2+/Calmodulin binding validated. |
| Phosphatase Activity Measurement | Catalytically active preparations (theoretical specific activity); D90N catalytic-dead mutant available as negative control. |
| Complex Formation Validation | Native structural integrity via optimal expression systems; supporting ternary complex (e.g., PPP3CC-FKBP1A-FK506) studies. |
| Lack of Controls | Clinical Benchmark Antibodies (biosimilars) included for assay validation and target engagement. |
| False Positives | Validated siRNA included for target-specificity confirmation in cellular assays. |
Live PPP3CC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The calcineurin inhibitor landscape is undergoing a paradigm shift from pan-inhibition (Cyclosporine, Tacrolimus) to isoform-selective targeting. While PPP3CC (the gamma/testis-specific isoform) remains in preclinical stages, it represents a high-value target for male contraceptive development, neuroprotection without immunosuppression, and potentially schizophrenia/neurological disorder modulation. Unlike the ubiquitously expressed PPP3CA (alpha), PPP3CC offers a tissue-specific mechanism to modulate sperm motility and neuronal calcium signaling while sparing T-cell function. The next wave of R&D focuses on allosteric inhibitors that exploit unique residues in the gamma isoform active site, protein-protein interaction disruptors targeting the PPP3CC-PPP3R2 interface, and emerging modalities such as PROTACs (targeted protein degraders) to achieve robust CNS penetrance and minimize renal/neurological toxicities associated with first-generation calcineurin inhibitors.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Isoform-Selective) | Baylor College of Medicine, NIH Chemical Genomics, Novartis, Astellas | Male Contraception, Immunosuppression | Selectivity Assay (Need matched isoform panel with >95% purity) |
| Peptide Inhibitors | Academic Consortiums | Neuroprotection (AD/PD) | Holoenzyme Disruption (Need PPP3R2 + PPP3CC full-length proteins) |
| Chemical Probes | SGC (Structural Genomics Consortium) | Target Validation | Phosphatase Activity (Need enzymatically active, endotoxin-controlled protein) |
| PROTAC / Degrader | Emerging Biotechs | Neurological Disorders, Schizophrenia | Ternary Complex Validation (Need high-purity PPP3CC and E3 ligase components) |
| Gene Therapy | Academic Spin-offs | Schizophrenia | Expression Validation (Need specific Benchmark Abs for detection) |